Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | GLS | O94925 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5591074 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CYP1A2CYP2C9CYP2C19ACHE | |
| SCHEMBL14381658 | 0.83 | CYP1A2 (0.49) | ALDH1A1CYP1A2CYP2C9CYP2C19ACHE | |
| SCHEMBL17789326 | 0.82 | ALDH1A1 (0.47) | ALDH1A1CYP1A2CYP2C9CYP2C19ACHE | |
| SCHEMBL12817939 | 0.81 | CYP1A2 (0.43) | ALDH1A1CYP1A2CYP2C9CYP2C19ACHE | |
| SCHEMBL17983066 | 0.80 | CYP1A2 (0.54) | CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL17983217 | 0.79 | ALDH1A1 (0.45) | ALDH1A1CYP1A2CYP2C9CYP2C19ACHE | |
| SCHEMBL4216778 | 0.78 | GAA (0.49) | ALDH1A1CYP1A2CYP2C9MAPTRECQL | |
| SCHEMBL4216777 | 0.78 | GAA (0.49) | ALDH1A1CYP1A2CYP2C9MAPTRECQL | |
| SCHEMBL6231333 | 0.78 | GAA (0.49) | ALDH1A1CYP1A2CYP2C9MAPTRECQL | |
| SCHEMBL14928448 | 0.78 | CYP1A2 (0.46) | ALDH1A1CYP1A2CYP2C9CYP2C19ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709500-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-7709500-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-7709500-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20050107428-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107428-A1 | Chemical compounds | CCR10, CCR3, CXCR5 | ALDH1A1 3120/4885CYP1A2 253/4885CYP2C9 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.